Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Comparison of accelerometer-derived physical activity levels between individuals with and without cancer: a UK Biobank study.

McDonald L, Oguz M, Carroll R, Thakkar P, Yang F, Dhalwani N, Cox A, Merinopoulou E, Malcolm B, Mehmud F, Ramagopalan S.

Future Oncol. 2019 Nov;15(33):3763-3774. doi: 10.2217/fon-2019-0443. Epub 2019 Oct 22.

2.

Automated extraction of treatment patterns from social media posts: an exploratory analysis in renal cell carcinoma.

Ramagopalan SV, Malcolm B, Merinopoulou E, McDonald L, Cox A.

Future Oncol. 2019 Nov;15(31):3587-3596. doi: 10.2217/fon-2019-0406. Epub 2019 Sep 4.

3.

Effect of long-acting aripiprazole monohydrate on inpatient encounters: A retrospective mirror image study.

Aguilar M, Malcolm B.

Ment Health Clin. 2019 Jul 1;9(4):258-262. doi: 10.9740/mhc.2019.07.258. eCollection 2019 Jul.

4.

Why does a point of care guided transfusion algorithm not improve blood loss and transfusion practice in patients undergoing high-risk cardiac surgery? A prospective randomized controlled pilot study.

Lehmann F, Rau J, Malcolm B, Sander M, von Heymann C, Moormann T, Geyer T, Balzer F, Wernecke KD, Kaufner L.

BMC Anesthesiol. 2019 Feb 18;19(1):24. doi: 10.1186/s12871-019-0689-7.

5.

Real-world data and the patient perspective: the PROmise of social media?

McDonald L, Malcolm B, Ramagopalan S, Syrad H.

BMC Med. 2019 Jan 16;17(1):11. doi: 10.1186/s12916-018-1247-8.

6.

A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.

Barsuglia JP, Polanco M, Palmer R, Malcolm BJ, Kelmendi B, Calvey T.

Prog Brain Res. 2018;242:121-158. doi: 10.1016/bs.pbr.2018.08.002. Epub 2018 Oct 25.

PMID:
30471678
7.

Application of dynamic modeling for survival estimation in advanced renal cell carcinoma.

Deniz B, Altincatal A, Ambavane A, Rao S, Doan J, Malcolm B, Michaelson MD, Yang S.

PLoS One. 2018 Aug 30;13(8):e0203406. doi: 10.1371/journal.pone.0203406. eCollection 2018.

8.

Cognitive load reduces the effects of optic flow on gait and electrocortical dynamics during treadmill walking.

Malcolm BR, Foxe JJ, Butler JS, Molholm S, De Sanctis P.

J Neurophysiol. 2018 Nov 1;120(5):2246-2259. doi: 10.1152/jn.00079.2018. Epub 2018 Aug 1.

9.

Essential oil of lavender in anxiety disorders: Ready for prime time?

Malcolm BJ, Tallian K.

Ment Health Clin. 2018 Mar 26;7(4):147-155. doi: 10.9740/mhc.2017.07.147. eCollection 2017 Jul.

10.

Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Malcolm BJ, Lee KC.

Ment Health Clin. 2018 Mar 23;7(1):39-45. doi: 10.9740/mhc.2017.01.039. eCollection 2017 Jan.

11.

Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.

Malcolm BJ, Polanco M, Barsuglia JP.

J Psychoactive Drugs. 2018 Jul-Aug;50(3):256-265. doi: 10.1080/02791072.2018.1447175. Epub 2018 Apr 2.

PMID:
29608409
12.

PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials.

Malcolm BA, Aerts CA, Dubois KJ, Geurts FJ, Marien K, Rusch S, Van Dijck AH, Verloes R, Vingerhoets J.

Antiviral Res. 2018 May;153:70-77. doi: 10.1016/j.antiviral.2018.03.005. Epub 2018 Mar 19.

PMID:
29567461
13.

Agribusiness Perspectives on Transgenic Wheat.

Malcolm B.

Methods Mol Biol. 2017;1679:113-126. doi: 10.1007/978-1-4939-7337-8_7.

PMID:
28913797
14.
15.

Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.

Feifel D, Malcolm B, Boggie D, Lee K.

J Affect Disord. 2017 Oct 15;221:283-288. doi: 10.1016/j.jad.2017.06.043. Epub 2017 Jun 20.

PMID:
28666206
16.

Long-term test-retest reliability of event-related potential (ERP) recordings during treadmill walking using the mobile brain/body imaging (MoBI) approach.

Malcolm BR, Foxe JJ, Butler JS, Mowrey WB, Molholm S, De Sanctis P.

Brain Res. 2019 Aug 1;1716:62-69. doi: 10.1016/j.brainres.2017.05.021. Epub 2017 May 19.

PMID:
28532853
17.

Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.

Thomas K, Malcolm B, Lastra D.

J Psychoactive Drugs. 2017 Nov-Dec;49(5):446-455. doi: 10.1080/02791072.2017.1320734. Epub 2017 May 8. Review.

PMID:
28481178
18.

Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom.

Claxton L, Hodgson R, Taylor M, Malcolm B, Pulikottil Jacob R.

Pharmacoeconomics. 2017 Feb;35(2):237-248. doi: 10.1007/s40273-016-0459-z.

PMID:
27787744
19.

The aging brain shows less flexible reallocation of cognitive resources during dual-task walking: A mobile brain/body imaging (MoBI) study.

Malcolm BR, Foxe JJ, Butler JS, De Sanctis P.

Neuroimage. 2015 Aug 15;117:230-42. doi: 10.1016/j.neuroimage.2015.05.028. Epub 2015 May 16.

20.

Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology.

Schneider EL, Ashley GW, Dillen L, Stoops B, Austin NE, Malcolm BA, Santi DV.

Eur J Pharm Biopharm. 2015 Jun;93:254-9. doi: 10.1016/j.ejpb.2015.04.003. Epub 2015 Apr 18.

PMID:
25900863
21.

Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK.

Claxton L, Malcolm B, Taylor M, Haig J, Leteneux C.

Drugs Aging. 2014 Nov;31(11):837-48. doi: 10.1007/s40266-014-0216-y.

22.

Recalibration of inhibitory control systems during walking-related dual-task interference: a mobile brain-body imaging (MOBI) study.

De Sanctis P, Butler JS, Malcolm BR, Foxe JJ.

Neuroimage. 2014 Jul 1;94:55-64. doi: 10.1016/j.neuroimage.2014.03.016. Epub 2014 Mar 15.

23.

Effects of a student pharmacist consultation on patient knowledge and attitudes about vaccines.

Chou TI, Lash DB, Malcolm B, Yousify L, Quach JY, Dong S, Yu J.

J Am Pharm Assoc (2003). 2014 Mar-Apr;54(2):130-7. doi: 10.1331/JAPhA.2014.13114.

PMID:
24632928
24.

The spread process of epidemic influenza in the continental United States, 1968-2008.

Malcolm BL.

Spat Spatiotemporal Epidemiol. 2014 Apr;8:35-45. doi: 10.1016/j.sste.2014.01.001. Epub 2014 Jan 22.

PMID:
24606993
25.

Rapid soil production and weathering in the Southern Alps, New Zealand.

Larsen IJ, Almond PC, Eger A, Stone JO, Montgomery DR, Malcolm B.

Science. 2014 Feb 7;343(6171):637-40. doi: 10.1126/science.1244908. Epub 2014 Jan 16.

PMID:
24436184
26.

A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.

Price D, Asukai Y, Ananthapavan J, Malcolm B, Radwan A, Keyzor I.

Appl Health Econ Health Policy. 2013 Jun;11(3):259-74. doi: 10.1007/s40258-013-0021-5.

27.

Reporter gene expression from LTR-circles as tool to identify HIV-1 integrase inhibitors.

Van Loock M, Hombrouck A, Jacobs T, Winters B, Meersseman G, Van Acker K, Clayton RF, Malcolm BA.

J Virol Methods. 2013 Feb;187(2):238-47. doi: 10.1016/j.jviromet.2012.11.016. Epub 2012 Nov 23.

PMID:
23178583
28.

Screening and rank ordering of reversible mechanism-based inhibitors of hepatitis C virus NS3 protease using electrospray ionization mass spectrometry.

Liu YH, Ramanathan L, Malcolm B, Njoroge G, Chan TY, Pramanik BN.

J Mass Spectrom. 2011 Aug;46(8):764-71. doi: 10.1002/jms.1948.

PMID:
21766396
29.

The rise of methicillin-resistant staphylococcus aureus in U.S. correctional populations.

Malcolm B.

J Correct Health Care. 2011 Jul;17(3):254-65. doi: 10.1177/1078345811401363. Epub 2011 May 13.

30.

A comparative analysis of the substrate permissiveness of HCV and GBV-B NS3/4A proteases reveals genetic evidence for an interaction with NS4B protein during genome replication.

Benureau Y, Warter L, Malcolm BA, Martin A.

Virology. 2010 Oct 25;406(2):228-40. doi: 10.1016/j.virol.2010.07.014. Epub 2010 Aug 11.

31.

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

Arasappan A, Bennett F, Bogen SL, Venkatraman S, Blackman M, Chen KX, Hendrata S, Huang Y, Huelgas RM, Nair L, Padilla AI, Pan W, Pike R, Pinto P, Ruan S, Sannigrahi M, Velazquez F, Vibulbhan B, Wu W, Yang W, Saksena AK, Girijavallabhan V, Shih NY, Kong J, Meng T, Jin Y, Wong J, McNamara P, Prongay A, Madison V, Piwinski JJ, Cheng KC, Morrison R, Malcolm B, Tong X, Ralston R, Njoroge FG.

ACS Med Chem Lett. 2010 Feb 15;1(2):64-9. doi: 10.1021/ml9000276. eCollection 2010 May 13.

32.

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.

Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J, Prongay A, Ralston R, Skelton A, Xia E, Zhang R, Njoroge FG.

Antimicrob Agents Chemother. 2010 Jun;54(6):2365-70. doi: 10.1128/AAC.00135-10. Epub 2010 Mar 22.

33.

Changes in familiarity and recollection across the lifespan: an ERP perspective.

Friedman D, de Chastelaine M, Nessler D, Malcolm B.

Brain Res. 2010 Jan 15;1310:124-41. doi: 10.1016/j.brainres.2009.11.016. Epub 2009 Nov 13.

34.

Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034.

Madison V, Prongay AJ, Guo Z, Yao N, Pichardo J, Fischmann T, Strickland C, Myers J Jr, Weber PC, Beyer BM, Ingram R, Hong Z, Prosise WW, Ramanathan L, Taremi SS, Yarosh-Tomaine T, Zhang R, Senior M, Yang RS, Malcolm B, Arasappan A, Bennett F, Bogen SL, Chen K, Jao E, Liu YT, Lovey RG, Saksena AK, Venkatraman S, Girijavallabhan V, Njoroge FG.

J Synchrotron Radiat. 2008 May;15(Pt 3):204-7. doi: 10.1107/S0909049507064229. Epub 2008 Apr 18.

35.

Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.

Prongay AJ, Guo Z, Yao N, Pichardo J, Fischmann T, Strickland C, Myers J Jr, Weber PC, Beyer BM, Ingram R, Hong Z, Prosise WW, Ramanathan L, Taremi SS, Yarosh-Tomaine T, Zhang R, Senior M, Yang RS, Malcolm B, Arasappan A, Bennett F, Bogen SL, Chen K, Jao E, Liu YT, Lovey RG, Saksena AK, Venkatraman S, Girijavallabhan V, Njoroge FG, Madison V.

J Med Chem. 2007 May 17;50(10):2310-8. Epub 2007 Apr 20.

PMID:
17444623
36.

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.

Venkatraman S, Bogen SL, Arasappan A, Bennett F, Chen K, Jao E, Liu YT, Lovey R, Hendrata S, Huang Y, Pan W, Parekh T, Pinto P, Popov V, Pike R, Ruan S, Santhanam B, Vibulbhan B, Wu W, Yang W, Kong J, Liang X, Wong J, Liu R, Butkiewicz N, Chase R, Hart A, Agrawal S, Ingravallo P, Pichardo J, Kong R, Baroudy B, Malcolm B, Guo Z, Prongay A, Madison V, Broske L, Cui X, Cheng KC, Hsieh Y, Brisson JM, Prelusky D, Korfmacher W, White R, Bogdanowich-Knipp S, Pavlovsky A, Bradley P, Saksena AK, Ganguly A, Piwinski J, Girijavallabhan V, Njoroge FG.

J Med Chem. 2006 Oct 5;49(20):6074-86.

PMID:
17004721
37.

Multiple substance dependence and course of alcoholism among Alaska native men and women.

Malcolm BP, Hesselbrock MN, Segal B.

Subst Use Misuse. 2006;41(5):729-41.

PMID:
16603457
38.

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V, Njoroge FG.

Antimicrob Agents Chemother. 2006 Mar;50(3):1013-20.

39.

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA.

Antiviral Res. 2006 Jun;70(2):28-38. Epub 2006 Jan 13.

PMID:
16448708
40.

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.

Tong X, Guo Z, Wright-Minogue J, Xia E, Prongay A, Madison V, Qiu P, Venkatraman S, Velazquez F, Njoroge FG, Malcolm BA.

Biochemistry. 2006 Feb 7;45(5):1353-61.

PMID:
16445277
41.

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.

Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, Bogen SL, Saksena AK, Njoroge FG, Veselenak RL, Pyles RB, Bourne N, Malcolm BA, Lemon SM.

J Biol Chem. 2006 Mar 24;281(12):8205-15. Epub 2005 Dec 13.

42.

Trans-complementation of HCV replication by non-structural protein 5A.

Tong X, Malcolm BA.

Virus Res. 2006 Feb;115(2):122-30. Epub 2005 Sep 15.

PMID:
16146661
43.

Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.

Arasappan A, Njoroge FG, Chan TY, Bennett F, Bogen SL, Chen K, Gu H, Hong L, Jao E, Liu YT, Lovey RG, Parekh T, Pike RE, Pinto P, Santhanam B, Venkatraman S, Vaccaro H, Wang H, Yang X, Zhu Z, Mckittrick B, Saksena AK, Girijavallabhan V, Pichardo J, Butkiewicz N, Ingram R, Malcolm B, Prongay A, Yao N, Marten B, Madison V, Kemp S, Levy O, Lim-Wilby M, Tamura S, Ganguly AK.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4180-4.

PMID:
16087332
44.

Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase.

Lu Z, Yin Z, James L, Syto R, Stafford JM, Koseoglu S, Mayhood T, Myers J, Windsor W, Kirschmeier P, Samatar AA, Malcolm B, Turek-Etienne TC, Kumar CC.

J Biomol Screen. 2004 Jun;9(4):309-21.

PMID:
15191648
45.

A continuous nonradioactive assay for RNA-dependent RNA polymerase activity.

Lahser FC, Malcolm BA.

Anal Biochem. 2004 Feb 15;325(2):247-54.

PMID:
14751259
46.

Conserved C-terminal threonine of hepatitis C virus NS3 regulates autoproteolysis and prevents product inhibition.

Wang W, Lahser FC, Yi M, Wright-Minogue J, Xia E, Weber PC, Lemon SM, Malcolm BA.

J Virol. 2004 Jan;78(2):700-9.

47.

The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR.

Virology. 2003 Jun 5;310(2):333-42.

48.

Dosage of treatment to sexual offenders: are we overprescribing?

Mailloux DL, Abracen J, Serin R, Cousineau C, Malcolm B, Looman J.

Int J Offender Ther Comp Criminol. 2003 Apr;47(2):171-84.

PMID:
12710363
49.

Quantitative estimation of viral fitness using Pyrosequencing.

Lahser FC, Wright-Minogue J, Skelton A, Malcolm BA.

Biotechniques. 2003 Jan;34(1):26-8. No abstract available.

50.

Binding affinities and geometries of various metal ligands in peptide deformylase inhibitors.

Madison V, Duca J, Bennett F, Bohanon S, Cooper A, Chu M, Desai J, Girijavallabhan V, Hare R, Hruza A, Hendrata S, Huang Y, Kravec C, Malcolm B, McCormick J, Miesel L, Ramanathan L, Reichert P, Saksena A, Wang J, Weber PC, Zhu H, Fischmann T.

Biophys Chem. 2002 Dec 10;101-102:239-47.

PMID:
12488004

Supplemental Content

Loading ...
Support Center